Skip to content

Efficacy and safety of Qianliebeixi capsule in the treatment of patients with chronic prostatitis (CP): a randomized, double-blind, controlled clinical trial

Efficacy and safety of Qianliebeixi capsule in the treatment of patients with chronic prostatitis (CP): a randomized, double-blind, controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025811
Enrollment
Unknown
Registered
2019-09-09
Start date
2020-07-02
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic prostatitis

Interventions

Experimental group:Qianlie Beixi Capsule + Tamsulosin Hydrochloride Simulator
Control group:Qianlie Beixi Capsule Simulator + Tamsulosin Hydrochloride
Joint group:Qianlie Beixi Capsule+Tamsulosin Hydrochloride

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1) Age 18 to 50 years; 2) with typical symptoms of chronic prostatitis type IIIB (different levels of urinary tract irritation and pelvic discomfort); 3) NIH-CPSI score >=15 points; 4) The disease history is more than 3 months; 5) B-ultrasound examination: the prostate size is normal; 6) tPSA<4ng/ml; 7) Prostatic fluid conventional white blood cells <10/HP.

Exclusion criteria

Exclusion criteria: 1) Patients with benign prostatic hyperplasia; 2) History of neurological lesions (such as neurogenic bladder dysfunction); 3) Suspected prostate cancer, urethral tumor or bladder cancer; 4) Those who have had a history of prostate surgery or invasive treatment (such as balloon angioplasty, transurethral microwave thermotherapy, urethral stent implantation, etc.); 5) Those who have had urethral stricture or deformity in the past; 6) Acute urinary tract infections; 7) The lower ureter stones; 8) Severe heart, liver and kidney dysfunction; 9) Testicular epididymis and spermatic cord disease; 10) Allergic or allergic to the ingredients of this product; 11) Taking other drugs that affect the trial within the last 3 months; 12) Those who cannot understand or fail to complete the trial and who have no legal capacity or self-awareness; 13) Those who participate in other clinical drug trials at the same time; 14) There are other factors that may affect the results of this test or may not be appropriate for the tester based on the investigator's judgment.

Design outcomes

Primary

MeasureTime frame
NIH-CPSI;

Secondary

MeasureTime frame
Prostate fluid WBC count and lecithin corpuscle count;

Countries

China

Contacts

Public ContactTie Zhou

Changhai Hospital

wenzhoutie@163.com+86 021-31166666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026